NeoGenomics is no longer being priced as a turnaround lab. The Fort Myers oncology diagnostics company spent the first half of the year proving that a richer test mix can lift revenue even when sample counts barely move, and the market has already paid up for that proof. Shares now sit near the top of the past-year range after management raised full-year revenue and the cash-earnings proxy it uses for operating profit. The debate has shifted from whether the mix story is real to whether the current capitalization already assumes that next-generation sequencing and a newly reimbursed residual-disease assay keep compounding from here.
The operating tension is that volume is not doing the work. Clinical tests rose about 2% in the second quarter, while average revenue per clinical test climbed to $515. Next-generation sequencing grew 26% and now contributes about one third of clinical revenue. That is why the top line can expand in the low teens while the lab processes almost the same number of tubes. Adjusted earnings before interest, taxes, depreciation, and amortization rose 36%, but reported profit only flipped positive because of an $11 million gain on the convertible-note refinance. Strip that gain and the company is still an operating-loss business selling a growth multiple.
Late August Medicare coverage for the RaDaR ST residual-disease assay in immunotherapy monitoring is the first post-print event that could change the mix again, this time by opening a longitudinal testing use case rather than another one-time tumor profile. Against that sits a capital structure that has already been marked to the new share price. The June notes convert well below the market, and a Department of Justice settlement still takes cash in the third quarter. Can average price per test keep rising if volumes stay this soft, and does residual-disease coverage become a revenue line before the multiple has to defend itself?